9/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?

The short peptide we are developing (JAL-TA9) is expected to be used as a safe and inexpensive fundamental treatment for AD beyond lecanemab, as shown in the table below.

Leave a Reply

Your email address will not be published. Required fields are marked *